Anti-CD19 CAR T as a feasible and safe therapy for refractory/relapsed mixed phenotype acute leukemia (MPAL) patients
Xiangqun Li1Ⅰ Kylan Chen2Ⅰ Hailong Zhang1Ⅰ Xian Zhang3,4Ⅰ Junfang Yang3,4Ⅰ Jing Liu1Ⅰ Jianwei Zheng1Ⅰ Fei Dong1, Yongbo Zhu1Ⅰ Jiao Yu1Ⅰ Haihong Zhang1Ⅰ Peihua Lu3,4Ⅰ Bo Chen1
1 Kecellitics Biotech Company Ltd, Beijing, China
2 College of Natural Sciences, University of Texas
3 Lu Daopei Hospital, Langfang, Hebei, China4 Lu Daopei Institute of Hematology, Beijing, China